FY2025 EPS Estimates for Immatics Reduced by Chardan Capital

Immatics N.V. (NASDAQ:IMTX) – Chardan Capital reduced their FY2025 earnings estimates for shares of Immatics in a research report issued to clients and investors on Monday, November 24th. Chardan Capital analyst Y. Livshits now forecasts that the company will earn ($1.76) per share for the year, down from their prior estimate of ($1.47). Chardan Capital has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Immatics’ current full-year earnings is ($0.72) per share.

IMTX has been the subject of several other reports. Zacks Research raised Immatics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 13th. Mizuho upped their target price on Immatics from $19.00 to $23.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Guggenheim lifted their target price on Immatics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immatics in a research note on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.25.

Immatics Stock Up 1.3%

IMTX stock opened at $10.75 on Thursday. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -10.54 and a beta of 1.24. The company’s fifty day simple moving average is $9.68 and its 200 day simple moving average is $7.15. Immatics has a 12-month low of $3.30 and a 12-month high of $11.25.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings data on Monday, November 17th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.01. Immatics had a negative net margin of 146.13% and a negative return on equity of 24.16%. The company had revenue of $6.10 million for the quarter, compared to analyst estimates of $12.53 million.

Institutional Trading of Immatics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE raised its stake in Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock worth $25,000 after buying an additional 2,231 shares during the period. Pale Fire Capital SE increased its holdings in shares of Immatics by 8.9% during the first quarter. Pale Fire Capital SE now owns 34,270 shares of the company’s stock valued at $155,000 after acquiring an additional 2,808 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its position in shares of Immatics by 8.3% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 47,635 shares of the company’s stock worth $406,000 after purchasing an additional 3,666 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Immatics by 28.7% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 31,894 shares of the company’s stock worth $172,000 after purchasing an additional 7,116 shares in the last quarter. Finally, Vontobel Holding Ltd. bought a new position in shares of Immatics in the 2nd quarter worth $59,000. 64.41% of the stock is owned by institutional investors.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.